{"id":331956,"date":"2026-10-29T12:50:29","date_gmt":"2026-10-29T07:20:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=331956"},"modified":"2026-10-29T12:50:29","modified_gmt":"2026-10-29T07:20:29","slug":"molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/","title":{"rendered":"3 Molecular Testing Company, National Pathology Network and Public Partnership Diagnostics Provider Stocks With a Strong Future Roadmap: Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics: ROE of 10.3% to 14.2% and FY22 to FY26 revenue CAGR of 7.6% to 16.8%. Prices as of 28 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three molecular testing and pathology lab stocks to watch are Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics. Their return on equity ranges from 10.3% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 16.8%. Molbio Diagnostics leads on both return on equity at 14.2% and revenue growth at 16.8% a year. Prices are based on the 28 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Molecular testing and pathology lab stocks let investors follow companies that serve a growing part of the Indian economy. Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics cover a point of care molecular testing company, a national pathology network and a government partnership diagnostics provider.<\/p>\n<p>This list covers three molecular testing and pathology lab stocks with complete current figures: Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#What_Are_Molecular_Testing_and_Pathology_Lab_Stocks\" title=\"What Are Molecular Testing and Pathology Lab Stocks?\">What Are Molecular Testing and Pathology Lab Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Molecular_Testing_and_Pathology_Lab_Stocks_at_a_Glance\" title=\"Molecular Testing and Pathology Lab Stocks at a Glance\">Molecular Testing and Pathology Lab Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Why_Do_Molecular_Testing_and_Pathology_Lab_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Molecular Testing and Pathology Lab Stocks Have a Strong Roadmap in India?\">Why Do Molecular Testing and Pathology Lab Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Why_Molbio_Diagnostics_Features_Among_These_Molecular_Testing_and_Pathology_Lab_Stocks\" title=\"Why Molbio Diagnostics Features Among These Molecular Testing and Pathology Lab Stocks\">Why Molbio Diagnostics Features Among These Molecular Testing and Pathology Lab Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Why_Metropolis_Healthcare_Features_Among_These_Molecular_Testing_and_Pathology_Lab_Stocks\" title=\"Why Metropolis Healthcare Features Among These Molecular Testing and Pathology Lab Stocks\">Why Metropolis Healthcare Features Among These Molecular Testing and Pathology Lab Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Why_Krsnaa_Diagnostics_Features_Among_These_Molecular_Testing_and_Pathology_Lab_Stocks\" title=\"Why Krsnaa Diagnostics Features Among These Molecular Testing and Pathology Lab Stocks\">Why Krsnaa Diagnostics Features Among These Molecular Testing and Pathology Lab Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Molbio_Diagnostics_vs_Metropolis_Healthcare_vs_Krsnaa_Diagnostics_on_Key_Financials\" title=\"Molbio Diagnostics vs Metropolis Healthcare vs Krsnaa Diagnostics on Key Financials\">Molbio Diagnostics vs Metropolis Healthcare vs Krsnaa Diagnostics on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Key_Risks_to_Check_Before_Investing_in_Molecular_Testing_and_Pathology_Lab_Stocks\" title=\"Key Risks to Check Before Investing in Molecular Testing and Pathology Lab Stocks\">Key Risks to Check Before Investing in Molecular Testing and Pathology Lab Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Final_Thoughts_on_Molecular_Testing_and_Pathology_Lab_Stocks\" title=\"Final Thoughts on Molecular Testing and Pathology Lab Stocks\">Final Thoughts on Molecular Testing and Pathology Lab Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#What_are_molecular_testing_and_pathology_lab_stocks\" title=\"What are molecular testing and pathology lab stocks?\">What are molecular testing and pathology lab stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Which_molecular_testing_and_pathology_lab_stocks_are_covered_in_this_list\" title=\"Which molecular testing and pathology lab stocks are covered in this list?\">Which molecular testing and pathology lab stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Why_do_molecular_testing_and_pathology_lab_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do molecular testing and pathology lab stocks have a strong future roadmap in India?\">Why do molecular testing and pathology lab stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#How_has_Molbio_Diagnostics_performed_financially\" title=\"How has Molbio Diagnostics performed financially?\">How has Molbio Diagnostics performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#How_has_Metropolis_Healthcare_performed_financially\" title=\"How has Metropolis Healthcare performed financially?\">How has Metropolis Healthcare performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#How_has_Krsnaa_Diagnostics_performed_financially\" title=\"How has Krsnaa Diagnostics performed financially?\">How has Krsnaa Diagnostics performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#What_risks_should_investors_check_before_buying_molecular_testing_and_pathology_lab_stocks\" title=\"What risks should investors check before buying molecular testing and pathology lab stocks?\">What risks should investors check before buying molecular testing and pathology lab stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/molecular-testing-company-national-pathology-network-and-public-partnership-diagnostics-provider-stocks-roadmap-questlist-list\/#Is_this_list_of_molecular_testing_and_pathology_lab_stocks_investment_advice\" title=\"Is this list of molecular testing and pathology lab stocks investment advice?\">Is this list of molecular testing and pathology lab stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Molecular_Testing_and_Pathology_Lab_Stocks\"><\/span><strong>What Are Molecular Testing and Pathology Lab Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Molecular testing and pathology lab stocks are listed companies that make portable molecular testing systems, run laboratories and collection centres across the country and provide radiology and pathology services through government hospital partnerships. Their earnings depend on test volumes, network reach and service mix.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Molecular_Testing_and_Pathology_Lab_Stocks_at_a_Glance\"><\/span><strong>Molecular Testing and Pathology Lab Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/molbio\/molbio-diagnostics-ltd-share-price-today\">Molbio Diagnostics<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,312.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,605<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">101.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.38<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/metropolis\/metropolis-healthcare-ltd-share-price-today\">Metropolis Healthcare<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">551.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10,780<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">53.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.15<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/krsnaa\/krsnaa-diagnostics-ltd-share-price-today\">Krsnaa Diagnostics<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">496.45<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,615<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">58.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.55<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Metropolis Healthcare and Krsnaa Diagnostics trade at a P\/E below the industry P\/E, while Molbio Diagnostics trades above it, which reflects the growth the market already expects. Readers comparing molecular testing and pathology lab stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Molecular_Testing_and_Pathology_Lab_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Molecular Testing and Pathology Lab Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Molecular testing and pathology lab stocks have a strong roadmap in India because rising health awareness, a shift toward preventive testing and wider access to organised diagnostics keep widening the market for these testing companies.<\/p>\n<ul>\n<li><strong>Preventive care.<\/strong> More people take regular health tests.<\/li>\n<li><strong>Wide networks.<\/strong> Collection points bring labs closer to patients.<\/li>\n<li><strong>Public partnerships.<\/strong> Government hospital tie ups add steady volumes.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Molbio_Diagnostics_Features_Among_These_Molecular_Testing_and_Pathology_Lab_Stocks\"><\/span><strong>Why Molbio Diagnostics Features Among These Molecular Testing and Pathology Lab Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the molecular testing and pathology lab stocks on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.<\/p>\n<p>Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.<\/p>\n<p>The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P\/E of 101.2, above the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.<\/p>\n<p><strong>What to watch:<\/strong> Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Metropolis_Healthcare_Features_Among_These_Molecular_Testing_and_Pathology_Lab_Stocks\"><\/span><strong>Why Metropolis Healthcare Features Among These Molecular Testing and Pathology Lab Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the testing and pathology shares on this list, Metropolis Healthcare, headquartered in Mumbai, is a pathology and diagnostics company that runs a national network of laboratories, patient service centres and collection points, and also serves hospitals and corporate clients.<\/p>\n<p>In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%.<\/p>\n<p>Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P\/E of 53.1, below the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> The company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.<\/p>\n<p><strong>What to watch:<\/strong> Follow test volumes per patient and the pace at which newer regions turn profitable.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Krsnaa_Diagnostics_Features_Among_These_Molecular_Testing_and_Pathology_Lab_Stocks\"><\/span><strong>Why Krsnaa Diagnostics Features Among These Molecular Testing and Pathology Lab Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Krsnaa Diagnostics provides radiology and pathology services through partnerships with government hospitals and through its own diagnostic centres across many states.<\/p>\n<p>The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P\/E of 16.6, below the industry P\/E of 58.4.<\/p>\n<p>Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.<\/p>\n<p><strong>What to watch:<\/strong> Track new contract wins, test volumes and the rollout of advanced imaging.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Molbio_Diagnostics_vs_Metropolis_Healthcare_vs_Krsnaa_Diagnostics_on_Key_Financials\"><\/span><strong>Molbio Diagnostics vs Metropolis Healthcare vs Krsnaa Diagnostics on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three molecular testing and pathology lab stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Molbio Diagnostics<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">782<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,455<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">164<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Metropolis Healthcare<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,246<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,671<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">191<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Krsnaa Diagnostics<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">470<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">816<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">101<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Molbio Diagnostics posts the highest return on equity in this group at 14.2%. Metropolis Healthcare has the largest FY26 revenue at Rs 1,671 crore, and Molbio Diagnostics shows the fastest revenue growth with a 16.8% compound annual rate. A useful habit with molecular testing and pathology lab stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Molecular_Testing_and_Pathology_Lab_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Molecular Testing and Pathology Lab Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these molecular testing and pathology lab stocks, the main points are: Long-term testing and pathology shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Test volumes.<\/strong> Footfall and test mix can vary with seasons.<\/li>\n<li><strong>Competition.<\/strong> Rivals can influence pricing and market share.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter molecular testing and pathology lab stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Molecular_Testing_and_Pathology_Lab_Stocks\"><\/span><strong>Final Thoughts on Molecular Testing and Pathology Lab Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Molecular testing and pathology lab stocks reward investors who follow demand trends, order books and margins together. Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics each have a clear plan to grow. Based on the 28 October 2026 close, Molbio Diagnostics trades at Rs 1,312.7, Metropolis Healthcare at Rs 551.2 and Krsnaa Diagnostics at Rs 496.45.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track molecular testing and pathology lab stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_molecular_testing_and_pathology_lab_stocks\"><\/span><strong>What are molecular testing and pathology lab stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Molecular testing and pathology lab stocks are listed companies that make portable molecular testing systems, run laboratories and collection centres across the country and provide radiology and pathology services through government hospital partnerships. Their earnings depend on test volumes, network reach and service mix. This list looks at three of them, Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_molecular_testing_and_pathology_lab_stocks_are_covered_in_this_list\"><\/span><strong>Which molecular testing and pathology lab stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics. Based on the 28 October 2026 close, Molbio Diagnostics traded at Rs 1,312.7, Metropolis Healthcare at Rs 551.2 and Krsnaa Diagnostics at Rs 496.45. Their return on equity ranges from 10.3% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 16.8%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_molecular_testing_and_pathology_lab_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do molecular testing and pathology lab stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Molecular testing and pathology lab stocks have a strong roadmap in India because rising health awareness, a shift toward preventive testing and wider access to organised diagnostics keep widening the market for these testing companies. The main drivers are as follows. Preventive care. More people take regular health tests. Wide networks. Collection points bring labs closer to patients. Public partnerships. Government hospital tie ups add steady volumes. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Molbio_Diagnostics_performed_financially\"><\/span><strong>How has Molbio Diagnostics performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P\/E of 101.2, above the industry P\/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Metropolis_Healthcare_performed_financially\"><\/span><strong>How has Metropolis Healthcare performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P\/E of 53.1, below the industry P\/E of 59.6. Looking ahead, the company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Krsnaa_Diagnostics_performed_financially\"><\/span><strong>How has Krsnaa Diagnostics performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore. The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P\/E of 16.6, below the industry P\/E of 58.4. Looking ahead, the company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_molecular_testing_and_pathology_lab_stocks\"><\/span><strong>What risks should investors check before buying molecular testing and pathology lab stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying molecular testing and pathology lab stocks. Test volumes. Footfall and test mix can vary with seasons. Competition. Rivals can influence pricing and market share. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_molecular_testing_and_pathology_lab_stocks_investment_advice\"><\/span><strong>Is this list of molecular testing and pathology lab stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are molecular testing and pathology lab stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Molecular testing and pathology lab stocks are listed companies that make portable molecular testing systems, run laboratories and collection centres across the country and provide radiology and pathology services through government hospital partnerships. Their earnings depend on test volumes, network reach and service mix. This list looks at three of them, Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which molecular testing and pathology lab stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics. Based on the 28 October 2026 close, Molbio Diagnostics traded at Rs 1,312.7, Metropolis Healthcare at Rs 551.2 and Krsnaa Diagnostics at Rs 496.45. Their return on equity ranges from 10.3% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 16.8%.\"}},{\"@type\":\"Question\",\"name\":\"Why do molecular testing and pathology lab stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Molecular testing and pathology lab stocks have a strong roadmap in India because rising health awareness, a shift toward preventive testing and wider access to organised diagnostics keep widening the market for these testing companies. The main drivers are as follows. Preventive care. More people take regular health tests. Wide networks. Collection points bring labs closer to patients. Public partnerships. Government hospital tie ups add steady volumes. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Molbio Diagnostics performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P\/E of 101.2, above the industry P\/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.\"}},{\"@type\":\"Question\",\"name\":\"How has Metropolis Healthcare performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P\/E of 53.1, below the industry P\/E of 59.6. Looking ahead, the company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.\"}},{\"@type\":\"Question\",\"name\":\"How has Krsnaa Diagnostics performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore. The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P\/E of 16.6, below the industry P\/E of 58.4. Looking ahead, the company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying molecular testing and pathology lab stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying molecular testing and pathology lab stocks. Test volumes. Footfall and test mix can vary with seasons. Competition. Rivals can influence pricing and market share. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of molecular testing and pathology lab stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Molecular Testing and Pathology Lab Stocks with a strong future roadmap: Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics. Compare price, valuation, return on equity and revenue growth as of 28 October 2026.<\/p>\n","protected":false},"author":29,"featured_media":331955,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,10055,7226,7909,18009,18007,18008],"class_list":["post-331956","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-krsnaa-diagnostics","tag-metropolis-healthcare","tag-molbio-diagnostics","tag-molecular-and-lab-services-stocks","tag-molecular-testing-and-pathology-lab-stocks","tag-testing-and-pathology-shares"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["331955"],"rank_math_title":["Molecular Testing, Pathology and Diagnostics Stocks"],"rank_math_description":["Compare 3 molecular testing and pathology lab stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 28 Oct 2026."],"rank_math_focus_keyword":["molecular testing and pathology lab stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-molecular-testing-company-national-pathology-network-and-public-partnership.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=331956"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331956\/revisions"}],"predecessor-version":[{"id":331957,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331956\/revisions\/331957"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/331955"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=331956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=331956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=331956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}